Biocryst Pharmaceuticals buy Wedbush
Start price
25.02.25
/
50%
€7.80
Target price
25.02.26
€14.28
Performance (%)
-28.91%
Price
30.01.26
€5.55
Summary
This prediction is currently active. The prediction for Biocryst Pharmaceuticals disappoints with a performance of -28.91%. This prediction currently runs until 25.02.26. The prediction end date can be changed by Wedbush at any time. Wedbush has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biocryst Pharmaceuticals | -3.479% | -3.479% |
| iShares Core DAX® | -1.432% | 0.000% |
| iShares Nasdaq 100 | -0.386% | -0.595% |
| iShares Nikkei 225® | 1.448% | 5.269% |
| iShares S&P 500 | 0.114% | -0.217% |
Comments by Wedbush for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is now covered by analysts at Wedbush. They set an "outperform" rating and a $15.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
Stopped prediction by Wedbush for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€7.60
30.06.25
30.06.25
€15.36
30.06.26
30.06.26
-27.02%
30.01.26
30.01.26
